Losartan and Emotion Processing

Healthy Clinical Trial

Official title:

Losartan Effects on the Extinction of Conditioned Fear in Humans

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03396523
• Other study ID #: UESTC-neuSCAN-25
• Status: Recruiting
• Phase: N/A
• Start date: January 4, 2018
• Est. completion date: December 31, 2018

Study information

• Verified date: June 2018
• Source: University of Electronic Science and Technology of China
• Contact: Weihua Zhao, Master
• Phone: 86-28-61830811
• Email: zarazhao.uestc[@]outlook.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of the study is to investigate the effect of losartan (50mg, single dose) on the extinction of conditioned fear

Description:

In a double-blind, between-subject, placebo controlled design the effects of a single dose of losartan (50mg) on fear extinction in healthy male participants will be examined. Participants will initially undergo a Pavlovian fear conditioning procedure, followed by the administration of 50mg losartan or placebo. 90 minutes after treatment subjects will undergo the fear extinction procedure. Neural activity and psychophysiological indices of arousal will be assessed by the simultaneous acquisition of functional magnetic resonance imaging (fMRI) and skin conductance data.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 70
• Est. completion date: December 31, 2018
• Est. primary completion date: October 31, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 30 Years

Eligibility

Inclusion Criteria:

• Healthy subjects without past or current psychiatric or neurological disorders

Exclusion Criteria:

• history of head injury

• medical or psychiatric illness

• hypertension

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• Losartan
administration of losartan (50 mg) (oral)
• Placebo Oral Tablet
administration of placebo (oral)

Locations

Country	Name	City	State
China	University of Electronic Science and Technology of China	Chengdu	Sichuan

Sponsors (1)

Lead Sponsor	Collaborator
University of Electronic Science and Technology of China

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Losartan effects on neural activity during fear extinction	Neural activity will be measured by functional magnetic resonance imaging (fMRI). Effects of treatment will be evaluated by comparing extinction-related neural activity in the core extinction network (prefrontal cortex, limbic regions) between the active treatment and the placebo group.	1 hour
Secondary	Losartan effects on skin conductance responses during fear extinction	Effects of treatment will be evaluated by comparing extinction-related skin conductance responses between the active treatment and the placebo group.	1 hour